摘要
Objective: Lenvatinib is a first-line multikinase inhibitor for advanced hepatocellular carcinoma (HCC), but resistance to the drug remains a major hurdle for its long-term anti-cancer activity. This resistance is thought to be due to overexpression of c-Met. This study aims to identify potential upstream microRNAs (miRNAs) that regulate c-Met, investigate the underlying mechanisms, and seek potential strategies that may reverse such resistance. Methods: Lenvatinib-resistant HCC (LR-HCC) cells were established from human HCC Huh7 and SMMC-7721 cells. Assays of cell proliferation, cell cycle distribution, apoptosis, RT-qPCR, Western blot analysis and immunohistochemistry were employed. Potential miRNAs were screened by miRNA-target prediction tools and their regulatory effects were evaluated by luciferase reporter assays. Xenograft tumor models were used to evaluate the therapeutic effects. Results: LR-HCC cells were refractory to lenvatinib-induced growth inhibition and apoptosis in vitro and in vivo. Sustained exposure of cells to lenvatinib resulted in increased expression and phosphorylation of c-Met, and c-Met inhibition enhanced the effects of lenvatinib in suppressing LR-HCC cells. Among eleven miRNA candidates, miR-128-3p displayed the most vigorous activity to negatively regulate c-Met and was downregulated in LR-HCC cells. MiR-128-3p mimics inhibited proliferation and induced apoptosis of LR-HCC cells, and enhanced the effects of lenvatinib in cell culture and animal models. MiR-128-3p and c-Met participate in the mechanisms underlying lenvatinib resistance through regulating Akt that mediates the apoptotic pathway and ERK (extracellular-signal-regulated kinase) modulating cell cycle progression. Conclusion: The present results indicate that the miR-128-3p/c-Met axis may be potential therapeutic targets for circumventing lenvatinib resistance in HCC and warrant further investigation.
学科与关键词
- Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expressionFu, Rongdang; Jiang, Shaotao; Li, Jieyuan; Chen, Huanwei*; Zhang, Xiaohong*MEDICAL ONCOLOGY, 2020, 37(4): 24.被引 62
- Targeting LINC01607 sensitizes hepatocellular carcinoma to Lenvatinib via suppressing mitophagyZhang, Yuxin; Zhang, Yujie; Tao, Haisu; Zhu, Jinghan; Lu, Yuanxiang; Cheng, Fangling; Xiong, Yixiao; Liu, Junjie; Cai, Guangzhen; Zhang, Zhanguo*; Liang, Huifang*; Chen, Yifa*; Zhang, Wanguang*Cancer Letters, 2023, 576: 216405.被引 1
- Genome-Wide CRISPR/Cas9 Library Screening Identified that DUSP4 Deficiency Induces Lenvatinib Resistance in Hepatocellular CarcinomaHuang, Shanzhou; Ma, Zuyi; Zhou, Qi; Wang, Aimei; Gong, Yuanfeng; Li, Zhenchong; Wang, Shujie; Yan, Qian; Wang, Dongping*; Hou, Baohua*; Zhang, Chuanzhao*International Journal of Biological Sciences, 2022, 18(11): 4357-4371.被引 15
